CJ Health Care held co-promotion agreement signing ceremony of

On Apr 14, CJ Health Care held co-promotion agreement signing ceremony of "Forxiga (ingredient: dapagliflozin)" which is Korea's first approved SGLT-2 inhibitors diabetes treatment, with AstraZeneca Korea in CJ Healthcare.

The two companies will jointly conduct sales and marketing of the product in generic hospitals, and CJ Health Care alone conduct sales and marketing in hospital and clinics....